Lakefront Biotherapeutics NV (LKFT) — Strategic Asset Allocation Index
Lakefront Biotherapeutics NV (LKFT) has a Strategic Asset Allocation Index of 1.5% as of March 2026. Strategic assets (PP&E of $- plus long-term investments of $47.93 Million) total $47.93 Million, measured against net assets of $3.25 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. For live market cap and overall valuation, see Lakefront Biotherapeutics NV market capitalisation.
SAAI
Strategic Assets
PP&E
Net Assets
Lakefront Biotherapeutics NV Strategic Asset Allocation Index (2022–2025)
This chart shows how Lakefront Biotherapeutics NV's Strategic Asset Allocation Index has evolved across 4 annual periods from 2022 to 2025. As of March 2026, the index stands at 1.5%, representing strategic assets of $47.93 Million against net assets of $3.25 Billion USD. See how leveraged is Lakefront Biotherapeutics NV's balance sheet to measure how much of total assets are equity-financed.
Annual Strategic Asset Allocation Index for Lakefront Biotherapeutics NV (2022–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Lakefront Biotherapeutics NV from 2022 to 2025, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. Also explore LKFT year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 1.4% | $46.81 Million | $- | $46.81 Million | $3.24 Billion | ▼ -7.3 pp |
| 2024 | 8.7% | $253.12 Million | $- | $253.12 Million | $2.90 Billion | ▲ +8.3 pp |
| 2023 | 0.5% | $13.57 Million | $- | $13.57 Million | $2.80 Billion | ▲ +0.5 pp |
| 2022 | 0.0% | $0.00 | $- | $0.00 | $2.53 Billion | — |